Amunix Pharmaceuticals, Inc.

Amunix Pharmaceuticals, Inc.

Amunix Pharmaceuticals, Inc.

Date Founded




Type of Company



Holding Companies

Company Description

Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA.

Contact Data
Trying to get in touch with decision makers at Amunix Pharmaceuticals, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

President & Chief Technology Officer

Chief Technical Operations Officer

Software Specialist

Board of Directors

Venture Partner at ARCH Venture Partners

Managing Partner, Life Sciences Team at Frazier Healthcare Partners

Co-Founder at Longitude Capital Management Co. LLC

Founder at Omega Fund Management LLC

Chief Financial Officer at Metacrine, Inc.

Chief Executive Officer at Amunix Pharmaceuticals, Inc.

Director at Amunix Pharmaceuticals, Inc.

Paths to Amunix Pharmaceuticals, Inc.
Potential Connections via
Relationship Science
Amunix Pharmaceuticals, Inc.
Recent Transactions
Details Hidden

Amunix Pharmaceuticals, Inc. raised money in a private placement transaction

Details Hidden

Frazier Healthcare Partners, Frazier & Co., Inc. purchase Amunix Pharmaceuticals, Inc.


9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. The company is founded by Jay P. Madan and Kendyle Woodard in 2012 and is headquartered in Raleigh, NC.

Details Hidden
Details Hidden

CCM uses different methods of analysis such as fundamental and quantitative. They look for companies that will benefit from access to incremental capital.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Amunix Pharmaceuticals, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Amunix Pharmaceuticals, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Amunix Pharmaceuticals, Inc..